Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival
- PMID: 19769657
- DOI: 10.1111/j.1442-2042.2009.02367.x
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival
Comment on
-
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.Int J Urol. 2009 Sep;16(9):726-31. doi: 10.1111/j.1442-2042.2009.02351.x. Int J Urol. 2009. PMID: 19769656 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical